MedTrace Logo

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

NCT07263490 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 462

Last updated 2026-04-13

No results posted yet for this study

Summary

The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.

Participants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.

Conditions

  • Pre-eclampsia
  • Oocyte Donation
  • Pre-Eclampsia; Complicating Pregnancy
  • Pre-Eclampsia; Mild
  • Pre-Eclampsia, Severe
  • Pre-eclampsia or Eclampsia With Pre-existing Hypertension
  • ART
  • Neonatal Morbidity
  • Neonatal Mortality
  • Placental Abruption
  • Gestational Diabetes
  • Preterm Labor
  • Post-partum Hemorrhage (PPH)
  • Intrauterine Growth Restriction (IUGR)
  • Hypertensive Disorders of Pregnancy

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • Gedeon Richter Ltd.

    collaborator INDUSTRY

  • Copenhagen University Hospital, Hvidovre

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-21
Primary Completion
2027-10-31
Completion
2028-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07263490 on ClinicalTrials.gov